

RESEARCH ARTICLE

Role of Lung Function Genes in the Development of Asthma

Hideyasu Yamada¹, Hironori Masuko¹, Yohei Yatagai¹, Tohru Sakamoto¹, Yoshiko Kaneko¹, Hiroaki Iijima², Takashi Naito², Emiko Noguchi³, Satoshi Konno⁴, Masaharu Nishimura⁴, Tomomitsu Hirota⁵, Mayumi Tamari⁵, Nobuyuki Hizawa^{1*}

1 Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, **2** Tsukuba Medical Center, Tsukuba, Ibaraki, Japan, **3** Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, **4** Laboratory for Respiratory Diseases, Center for Genomic Medicine, Institute of Physical and Chemical Research, Tsurumi, Kanagawa, Japan, **5** First Department of Medicine, School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan

* hironori816@yahoo.co.jp



OPEN ACCESS

Citation: Yamada H, Masuko H, Yatagai Y, Sakamoto T, Kaneko Y, Iijima H, et al. (2016) Role of Lung Function Genes in the Development of Asthma. PLoS ONE 11(1): e0145832. doi:10.1371/journal.pone.0145832

Editor: Chunxue Bai, Zhongshan Hospital Fudan University, CHINA

Received: August 9, 2015

Accepted: December 9, 2015

Published: January 11, 2016

Copyright: © 2016 Yamada et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Although our previous GWAS failed to identify SNPs associated with pulmonary function at the level of genomewide significance, it did show that the heritability for FEV₁/FVC was 41.6% in a Japanese population, suggesting that the heritability of pulmonary function traits can be explained by the additive effects of multiple common SNPs. In addition, our previous study indicated that pulmonary function genes identified in previous GWASs in non-Japanese populations accounted for 4.3% to 12.0% of the entire estimated heritability of FEV₁/FVC in a Japanese population. Therefore, given that many loci with individual weak effects may contribute to asthma risk, in this study, we created a quantitative score of genetic load based on 16 SNPs implicated in lower lung function in both Japanese and non-Japanese populations. This genetic risk score (GRS) for lower FEV₁/FVC was consistently associated with the onset of asthma ($P = 9.6 \times 10^{-4}$) in 2 independent Japanese populations as well as with the onset of COPD ($P = 0.042$). Clustering of asthma patients based on GRS levels indicated that an increased GRS may be responsible for the development of a particular phenotype of asthma characterized by early onset, atopy, and severer airflow obstruction.

Introduction

Reduced lung function at birth is a risk factor for asthma at 10 years of age [1]. Recently, genes implicated in fetal lung development have also been reported to influence asthma susceptibility and treatment response, supporting the involvement of deregulated lung development in the early ontogeny of asthma [2]. Adverse factors affecting lung development during fetal life and early childhood reduce the attainment of maximum lung function and accelerate lung function decline in adulthood, thereby predisposing individuals to reduced lung function and increased respiratory morbidity, particularly asthma and COPD, throughout life [3]. We have previously reported that *TSLP* gene variants, as a potential susceptibility locus to asthma [4], was

associated with lower lung function in healthy individuals, which is also in line with the contention that genetic determinants of lung function influence susceptibility to asthma [5]. In addition, several cluster analyses of asthmatic patients including ours indicated that lung function was among the important discriminating factors of the asthma phenotype [6, 7].

To date, genomewide association studies (GWASs) on pulmonary function including predicted percentage of forced expiratory volume in 1 second (%FEV₁) and ratio of forced expiratory volume in 1 second to forced vital capacity (FEV₁/FVC) have identified a number of risk loci in multiethnic populations [8–13]. Although our previous GWAS failed to identify SNPs associated with pulmonary function at the level of genomewide significance in a Japanese population, it did demonstrate that the heritability of pulmonary function can be explained by additive effects of multiple common SNPs, providing compelling evidence for a strong genetic influence on FEV₁/FVC [14]. Furthermore, our study indicated that lung function genes identified in previous GWASs in non-Japanese populations accounted for 4.3% to 12.0% of the entire estimated heritability of FEV₁/FVC in a Japanese population. Therefore, in the current study, we constructed a multi-SNP genetic risk score (GRS) for reduced FEV₁/FVC using genotype information for 16 genes associated with lower FEV₁/FVC in a GWAS of Japanese populations as well as in previous GWASs of non-Japanese populations. In this study, we investigated the relationship between the onset of asthma and genetic susceptibility to lower lung function as indicated by a multi-SNP GRS, and also attempted to identify a relevant asthma phenotype associated with an increased multi-SNP genetic score.

Materials and Methods

Ethics Statement

This study was approved by the Human Genome Analysis and Epidemiology Research Ethics Committee of the University of Tsukuba and by the Human Genome/Gene Analysis Research Ethics Review Committees of the Tsukuba Medical Center, RIKEN, and the Hokkaido University School of Medicine. Written informed consent was obtained from each participant in accordance with institutional requirements and the principles of the Declaration of Helsinki (IRB approval date: January 31st, 2008; IRB number: 2008-01-31).

Study populations

We defined 3 cohorts. (1) “Tsukuba cohort”: 1364 healthy adults who visited the Tsukuba Medical Center for an annual health checkup and 578 asthmatic patients from the Tsukuba University Hospital and its affiliated hospitals [5, 6, 15]. For the Tsukuba cohort, we conducted GWAS genotyping in 967 healthy adults and 244 asthmatic patients [14, 15]. (2) “Hokkaido cohort”: 998 healthy adults and 565 asthmatic patients from the Hokkaido University Hospital and its affiliated hospitals [15, 16]. (3) “COPD cohort”: 562 COPD patients were studied. Of those, 307 patients were from the Hokkaido University Hospital and its affiliated hospitals [17]; the other 255 patients were newly recruited at the University of Tsukuba and its affiliated hospitals. The participants’ characteristics are summarized in [S1 Table](#). The data were presented as means ± SDs unless otherwise indicated.

Diagnosis criteria for asthma and COPD

Asthma was diagnosed by respiratory physicians according to the American Thoracic Society criteria [15]. COPD patients were enrolled when they showed chronic irreversible airflow limitation defined by an FEV₁/FVC < 70% after the inhalation of a β₂-agonist. Patients with COPD were carefully screened to exclude those with asthma [17]. Patients were also excluded

if they had other significant respiratory diseases, such as lung cancer, eosinophilic pneumonia, or pulmonary tuberculosis, on the basis of the questionnaire and chest X-ray results [5, 14, 15]

Pulmonary function data

Spirometry was required in order to meet the criteria established by the Japanese Respiratory Society (JRS) [18]. For the 1364 healthy adults who visited the Tsukuba Medical Center for an annual health checkup, pulmonary function was measured using an electronic spirometer (Autospiro series; Minato Medical Science, Osaka, Japan), as described previously [14, 19]. Briefly, well-trained spirometry technicians continuously monitored the procedure and reviewed the flow-volume curves to ensure adherence to the standards. Participants performed up to 3 forced expiratory maneuvers so that acceptable maneuvers could be obtained. Broncho-dilation was not applied. Annual decline of FEV₁ was calculated as previously described [19]. Data for FEV₁/FVC were available for all the participants, and data for annual decline of FEV₁ were available for 803 nonasthmatic, non-COPD individuals [19].

Genotyping

Two hundred forty-four patients with asthma and 967 nonasthmatic, non-COPD controls underwent GWAS genotyping [14, 15]. For those individuals without GWAS genotyping (899 asthmatic patients, 562 COPD patients, and 1395 nonasthmatic, non-COPD healthy individuals), genotypes for 16 SNPs were defined using the TaqMan allele-specific amplification method (Applied Biosystems, Foster City, CA, USA), as described previously [4].

Statistical analysis

Considering the presence of allelic heterogeneity and different linkage disequilibrium patterns according to different ethnicities, 24 genes previously associated with FEV₁/FVC with probability values less than 5.0×10^{-8} (S2 Table) were tested for gene-level replications rather than for SNP-level replications in Japanese nonasthmatic, non-COPD individuals (N = 967) in the Tsukuba cohort [14]. We selected a top SNP with the strongest statistical evidence of association in each region extending ± 100 kb from each candidate gene for lung function, as described previously [14]. Because 16 of the 24 genes were nominally associated with FEV₁/FVC in the Japanese nonasthmatic, non-COPD individuals, we used the genotype information from these 16 genes to calculate the multi-SNP genetic risk score (GRS) for lower FEV₁/FVC in each participant. The GRS, which combines the modest effects of multiple SNPs into a single variable, is calculated as the weighted sum of the number of high-risk alleles, where the GRS for person *i* is

$$GRS_i = \sum_{k=1}^{16} |\beta_k| RA_k$$

GRS_{*i*}: GRS for individual *i*

β_{*k*}: regression coefficient of SNP_{*k*} as the weight of each risk allele derived from our GWAS for FEV₁/FVC

RA_{*k*}: number of risk alleles for SNP_{*k*} (0, 1, or 2)

The score was then divided by the highest risk score multiplied by 100 to rescale the scores to a range between 0 and 100. We used a linear mixed model (SPSS version 22) to compare the GRSs of healthy participants and of patients with asthma or COPD. The standardized coefficient “β” was selected as the weight (instead of, for example, simply counting the number of

risk alleles) because it considers both the expected magnitude and direction of effect of an individual SNP.

To estimate the dose effect of a GRS for asthma, using 1143 patients with asthma and 2362 healthy adults, we conducted a Cochran-Armitage trend test for the prevalence of asthmatic patients according to the different ranges of the GRS using R software (version 3.1.1) [20].

To examine whether the significant association between a GRS and asthma is driven by a single SNP, the association analysis was repeated by recalculating the GRS after excluding the genotype information from each of the 16 SNPs (a leave-one-out sensitivity analysis).

To identify distinctive patient characteristics related to an increased GRS level, we applied k-means cluster analysis to the asthmatic patients by including the GRS as a discriminating variable. For this cluster analysis, among a total of 1143 asthma patients in the study, 1063 patients with complete data on GRS, age at onset, and %FEV₁ were studied. Because several cluster analyses of asthma including ours showed that age at onset of asthma and %FEV₁ were the most important discriminators for asthma [6], in addition to the GRS, age at onset of asthma and %FEV₁ were intentionally selected for this cluster analysis. Differences in demographic and clinical characteristics between the resulting clusters were analyzed using ANOVA for continuous normally distributed variables, chi-squared tests for categorical variables, and the Kruskal-Wallis test for non-normally distributed variables. Although our previous cluster analysis identified 6 clusters largely based on age at onset of asthma and %FEV₁ [6], in the current study, the clustering that resulted in 5 groups was chosen for further analysis because of a clinical judgment that going from 5 to 6 groups resulted in patient clinical characteristics becoming more homogeneous rather than more distinct; especially, the number of clusters (k) that gave the maximum difference in the GRS score among the k clusters was 5 (S3 Fig). Then, given the 5 distinct clusters, we applied multinomial logistic regression analysis to examine association of a GRS with each of the 5 asthma clusters, which was adjusted for sex, age, atopy, smoking index group, and the cohorts.

To explore the biologic pathways related to a GRS, the Gene Relationships Among Implicated Loci (GRAIL) program was applied [21]. Briefly, GRAIL is a text mining tool that identifies nonrandom, evidence-based links between genes using PubMed abstracts. On the basis of the textual relationships between genes, GRAIL assigns a probability value to each region suggesting its degree of functional connectivity among genes at different loci. As input, we uploaded 16 SNPs used for the construction of a GRS. The GRAIL algorithm is available online at <https://www.broadinstitute.org/mpg/grail/>. We used the VIZ-GRAIL software (<http://www.broadinstitute.org/mpg/grail/vizgrail.html>) [22], which was implemented as 2 separate perl scripts, to visualize the results from the GRAIL analysis with default parameters. To explore the biologic relevance of a GRS, we also conducted pathway enrichment analysis for FEV₁/FVC using MetaCore™ software (Thomson Reuters, Philadelphia, PA, USA), an integrated software suite for functional analysis of all omics data, which connects the inputted SNPs to biologic effect or function to define the biologic relevance of the SNPs to lower lung function. We uploaded SNPs with probability values less than 0.05 in our GWAS of FEV₁/FVC ($n = 24,309$) for the enrichment analysis, and we then compared the results of GRAIL and MetaCore™ to identify possible clues to the molecular events leading to asthma.

Results

Among the 24 genes associated with FEV₁/FVC in 6 previous GWASs in non-Japanese populations, we found that 16 genes were nominally associated with FEV₁/FVC in a Japanese non-asthmatic, non-COPD population (S3 Table). A multi-SNP genetic risk score, or GRS, calculated on the basis of these 16 SNPs for healthy individuals in the Tsukuba cohort follows a

Table 1. Association between genetic risk score and onset of asthma or COPD.

cohort	Tsukuba cohort		Hokkaido cohort		Combined		Combined (smoking index ≤ 200)		COPD cohort	
	HV	BA	HV	BA	HV	BA	HV	BA	HV	COPD
Number	1364	578	998	565	2362	1143	1604	857	2362	562
GRS (mean)	56.06	56.79	56.09	56.96	56.07	56.87	55.97	56.73	56.07	56.53
GRSh (SD)	7.2	6.7	7.6	7.3	7.4	7.0	7.3	7.1	7.4	6.8
<i>P</i> value	0.037		0.014 ^b		0.0022		0.013		0.021 ^b	
<i>P</i> value (corrected) ^a	0.033		0.007 ^b		9.6×10 ⁻⁴		0.0020		-	

HV, healthy volunteer; BA, bronchial asthma; COPD, chronic obstructive pulmonary disease; SD, standard deviation

^aCorrected for sex, age, smoking index group, and atopy. In the combined analysis, cohort effects was also adjusted using the random effect model.

^bone-sided test

doi:10.1371/journal.pone.0145832.t001

normal distribution (S1 Fig). The GRS for lower FEV₁/FVC was significantly correlated with FEV₁/FVC in 1364 healthy individuals in the Tsukuba cohort ($R^2 = 0.040$, $P = 4.1 \times 10^{-14}$), but not with an annual decline in FEV₁ in 803 healthy individuals ($R^2 = 0.0001$, $P = 0.34$) (S2 Fig).

Compared with GRS levels in healthy individuals, we found significantly higher levels of GRS in patients with asthma in the Tsukuba cohort (P value = 0.033) (Table 1). We replicated this significant association between a GRS and asthma in the independent Hokkaido cohort (P value = 0.014). GRS levels were consistently higher in patients with asthma than in those in healthy adults; in the combined analysis of the Tsukuba and Hokkaido cohorts, higher levels of GRS were associated with the presence of asthma with the adjusted P value of 9.6×10^{-4} . These results did not change when individuals with a smoking history of over 10 pack-years were excluded from the analysis. In addition, GRS levels were also significantly higher in patients with COPD (Table 1).

The Cochran-Armitage trend test showed that the prevalence of asthma increased as GRS levels increased ($P = 0.0059$) (Fig 1). In contrast, the prevalence of atopic status did not change according to GRS levels ($P = 0.46$), indicating that association between the GRS and presence of asthma was independent of atopic status.

In the sensitivity analysis, we calculated a GRS based on 15 SNPs excluding each of the 16 SNPs (S4 Table). Every GRS calculated based on each of the 15 SNPs was also significantly associated with asthma, suggesting that none of the single SNPs drives the significant association between a GRS and asthma in the current study.

Our cluster analysis revealed 5 distinct asthmatic clusters (Fig 2). The cluster with the highest GRS ($n = 197$) was characterized by the youngest age at onset, moderate-to-severe lung function, the highest levels of total IgE, the highest prevalence of atopy (sensitizations to common inhaled allergens), and the lowest prevalence of smokers (S5 Table). In a multinomial logistic regression analysis, the strongest association between GRS levels and asthma was found in this particular cluster ($P = 3.6 \times 10^{-5}$, S6 Table).

To explore the biologic relevance of a GRS, we applied the top SNPs at 16 genes to the GRAIL program (Fig 3). For each SNP, GRAIL identified the genomic region in linkage disequilibrium and identified the overlapping genes. It then checked to see how many other loci already known to be associated with FEV₁/FVC contained functionally related genes. GRAIL determined the corresponding probability values for all gene–gene connections. The outer ring contains the input SNPs, and the inner ring shows all possible genes corresponding to each




Fig 1. Prevalence of asthma according to GRS levels. The X-axis shows the GRS ranges. The left Y-axis shows the number of healthy individuals and asthmatic patients for each GRS range. The right Y-axis shows the percentages of asthmatic patients and atopic individuals for each GRS range. The upper line shows the percentage of atopic individuals for each given GRS range. The lower line shows the percentage of asthmatic patients for each given GRS range. Atopy was defined as the presence of specific IgE antibody toward at least 1 common inhaled allergen. HV, healthy volunteer, BA, bronchial asthma.

doi:10.1371/journal.pone.0145832.g001

SNP locus. GRAIL indicated the presence of possible underlying biologic networks across these 16 loci. *FAM13A*, one of the genes annotated by the 16 SNPs, was the most functionally connected gene when that locus was scored against the 15 other validated risk loci (S7 Table). MetaCore™ revealed several pathways associated with FEV₁/FVC using the results of our GWAS (S8 Table). Among the top 20 pathways, two, “Signal transduction calcium signaling” and “Development regulation of epithelial-to-mesenchymal transition (EMT),” included genes that were annotated by GRAIL based on the 16 SNPs. Specifically, the EMT pathway contained 3 genes: *TGFB2*, *TNF*, and *NOTCH4*.

Discussion

The GRS level for lower FEV₁/FVC calculated based on the 16 SNPs was significantly higher in patients with asthma than in healthy adults, suggesting that a genetic susceptibility to lower lung function may predispose to asthma. Although both reduced growth and accelerated lung function decline lead to lower lung function levels in adults, given that the GRS calculated using 16 SNPs was not associated with annual lung function decline in the healthy participants, we believe that these 16 SNPs (or gene pathways involving these 16 SNPs) may be involved in the deregulated lung growth or development rather than in the accelerated decline of lung function. In support of this contention, lung function genetic variants identified in adults including *ARMC2*, *FAM13A*, *GPR126*, *KCNE2*, *NCR3*, *PID1*, *RARB*, and *THSD4* were recently




Fig 2. Differences in GRS, age at onset, and pFEV₁ among asthma clusters. The left Y-axis shows the mean GRS for each cluster. The right Y-axis shows the mean age at onset asthma and the mean pFEV₁ for each cluster. pFEV₁, percent predicted forced expiratory volume in 1 second.

doi:10.1371/journal.pone.0145832.g002

associated with the development of lung function measures such as FEF50 and PD20 during early childhood [23].

We found that a GRS was associated with COPD as well as with asthma. The present study, therefore, may identify a common susceptibility factor underlying asthma and COPD, stressing the importance and implications of these genetic variants in the development of lung function in early life and later progression to asthma and COPD [24]. Accordingly, our findings support the Dutch hypothesis that airway obstruction associated with asthma and COPD is related to different expressions of a primary abnormality in the airways and that both host and environmental factors play a part in the pathogenesis [25]. Alternatively, our findings suggest that the asthma-COPD overlap can have its origins in childhood [26]

The difference in the levels of GRS between healthy individuals and asthmatic patient was rather small, which suggested that contribution of genetic susceptibility to lower lung function to asthma is restricted to particular subphenotypes of asthma. Indeed, our clustering of asthma patients according to GRS levels showed that the GRS was specifically related to a particular phenotype characterized by early-onset of the disease, atopy, and severer airflow obstruction, suggesting that deregulated lung function development ascribed to a GRS might be an important genetic determinant specific to this particular phenotype. In the Severe Asthma Research Program cohort, a similar cluster was identified that was characterized by early-onset atopic asthma with advanced airflow limitation. The prevalence of this cluster was 18%, and the children in this cluster had the highest exhaled nitric oxide values, the highest extent of health-care use, and the highest daily doses of ICS, and most were receiving at least 3 asthma controller medications [27]. The “Environment and Childhood Asthma” birth cohort study in Oslo also




Fig 3. Graphic representation of functional connections between genes corresponding to the 16 SNPs. GRAIL found connections among genes in 16 loci. The outer circle shows the 16 SNPs used for the calculation of GRS. The internal ring represents the genes near each SNP. The literature-based functional connectivity between these genes with lines drawn between them—the redder and thicker the line is, the stronger the connectivity is between the genes.

doi:10.1371/journal.pone.0145832.g003

identified a similar asthma phenotype characterized by impaired lung function from birth throughout childhood with atopic dermatitis and allergic rhinitis [28]. Our clustering allowed greater specificity for a GRS as a genetic marker to identify this particular asthma phenotype/endotype related to deregulated lung function as well as better understanding of the mechanisms associated with the heterogeneity of severe asthma.

Our pathway analysis using GRAIL and MetaCore™ showed that molecules such as *TGFB2*, *TNF*, and *NOTCH4* that are related to the epithelial-mesenchymal transition (EMT) pathway could be responsible for the biologic relevance of a GRS. The EMT is a process whereby

epithelial cells gradually transform into mesenchyme-like cells losing their epithelial functionality and characteristics. EMT is a physiologic phenomenon involved in lung development [29] and is also implicated in aberrant repair of the epithelium and accumulation of fibroblasts (tissue remodeling) in specific chronic bronchial pathologies, such as asthma and COPD [26]. Accordingly, together with our pathway analysis, the biologic relevance of a GRS, which was associated with both lung function and asthma or COPD, may involve the EMT process in the lung.

There are some limitations to this study. Even though the 16 genes used to create a GRS were selected on the basis of the previous GWASs conducted in non-Japanese populations, all the study participants were Japanese, and therefore the analysis provides limited information on other ethnic groups and may not reflect the overall asthma population. In addition, although the clustering of asthma patients using a GRS gave some implication underlying the heterogeneity of asthma, the likelihood always exists of spurious findings being generated by chance. Thus, further replication should aim to confirm these results, particularly given that the levels of significance in the study were not overwhelming.

In conclusion, we have identified a multi-SNP genetic marker, a GRS based on 16 SNPs, associated with a specific asthma phenotype related to genetic susceptibility to lower lung function. By providing important insights into the pathways underlying the development of asthma, the findings of this study may help us to understand the complexity of asthma phenotypes and also to appropriately select patients for more targeted prevention and treatments in the future.

Supporting Information

S1 Fig. Histogram of genetic risk scores (GRS) in healthy Japanese individuals. GRS in non-asthmatic, non-COPD healthy individuals of the Tsukuba cohort (N = 1364). The solid line indicates normal distribution.

(TIF)

S2 Fig. Correlation between genetic risk score and FEV₁/FVC or annual decline in FEV₁ in healthy individuals. FEV₁/FVC (a) or annual decline in FEV₁ (b). Linear approximation is shown by the fine black line (a).

(TIF)

S3 Fig. Differences in the GRS among the given asthma clusters according to the number of clusters. When *k*-means cluster analysis was repeated for the number of clusters (*k*) 3, 4, 5, 6, or 7, the maximum difference in the GRS among the *k* asthma clusters was obtained for *k* = 5 (ANOVA *F* = 4.8, *P* < 0.001).

(TIF)

S1 Table. Demographic characteristics of the study cohorts.

(DOCX)

S2 Table. Susceptibility genes to pulmonary function traits in previous 6 GWASs.

(DOCX)

S3 Table. Sixteen genes associated with FEV₁/FVC in previous GWASs are nominally replicated in Japanese.

(DOCX)

S4 Table. Association between GRS (by 15 SNPs) and asthma.

(DOCX)

S5 Table. Characteristics of the asthma clusters.

(DOCX)

S6 Table. Association between genetic risk score and asthma clusters.

(DOCX)

S7 Table. Functionally connected genes in GRAIL.

(DOCX)

S8 Table. Top 20 pathways implicated by MetaCore™.

(DOCX)

Author Contributions

Conceived and designed the experiments: HY TS NH. Performed the experiments: HY YY HM TS YK. Analyzed the data: HY YY HM TS EN TH MT NH. Contributed reagents/materials/analysis tools: YK HI TN SK MN. Wrote the paper: HY TS NH.

References

1. Haland G, Carlsen KC, Sandvik L, Devulapalli CS, Munthe-Kaas MC, Pettersen M, et al. Reduced lung function at birth and the risk of asthma at 10 years of age. *N Engl J Med*. 2006; 355(16):1682–9. Epub 2006/10/20. doi: [10.1056/NEJMoa052885](https://doi.org/10.1056/NEJMoa052885) PMID: [17050892](https://pubmed.ncbi.nlm.nih.gov/17050892/).
2. Sharma S, Kho AT, Chhabra D, Qiu W, Gaedigk R, Vyhldal CA, et al. Glucocorticoid genes and the developmental origins of asthma susceptibility and treatment response. *Am J Respir Cell Mol Biol*. 2015; 52(5):543–53. Epub 2014/09/06. doi: [10.1165/rcmb.2014-0109OC](https://doi.org/10.1165/rcmb.2014-0109OC) PMID: [25192440](https://pubmed.ncbi.nlm.nih.gov/25192440/).
3. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. *The Lancet Respiratory medicine*. 2013; 1(9):728–42. Epub 2014/01/17. doi: [10.1016/s2213-2600\(13\)70118-8](https://doi.org/10.1016/s2213-2600(13)70118-8) PMID: [24429276](https://pubmed.ncbi.nlm.nih.gov/24429276/).
4. Harada M, Hirota T, Jodo AI, Hitomi Y, Sakashita M, Tsunoda T, et al. Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. *Am J Respir Cell Mol Biol*. 2011; 44(6):787–93. Epub 2010/07/27. doi: [10.1165/rcmb.2009-0418OC](https://doi.org/10.1165/rcmb.2009-0418OC) PMID: [20656951](https://pubmed.ncbi.nlm.nih.gov/20656951/); PubMed Central PMCID: [PMCPmc3159073](https://pubmed.ncbi.nlm.nih.gov/PMC3159073/).
5. Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, et al. Lower FEV1 in non-COPD, non-asthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes. *International journal of chronic obstructive pulmonary disease*. 2011; 6:181–9. Epub 2011/04/07. doi: [10.2147/copd.s16383](https://doi.org/10.2147/copd.s16383) PMID: [21468164](https://pubmed.ncbi.nlm.nih.gov/21468164/); PubMed Central PMCID: [PMCPmc3064418](https://pubmed.ncbi.nlm.nih.gov/PMC3064418/).
6. Kaneko Y, Masuko H, Sakamoto T, Iijima H, Naito T, Yatagai Y, et al. Asthma phenotypes in Japanese adults—their associations with the CCL5 and ADRB2 genotypes. *Allergology international: official journal of the Japanese Society of Allergology*. 2013; 62(1):113–21. doi: [10.2332/allergolint.12-OA-0467](https://doi.org/10.2332/allergolint.12-OA-0467) PMID: [23267209](https://pubmed.ncbi.nlm.nih.gov/23267209/).
7. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *American journal of respiratory and critical care medicine*. 2010; 181(4):315–23. Epub 2009/11/07. doi: [10.1164/rccm.200906-0896OC](https://doi.org/10.1164/rccm.200906-0896OC) PMID: [19892860](https://pubmed.ncbi.nlm.nih.gov/19892860/); PubMed Central PMCID: [PMCPMC2822971](https://pubmed.ncbi.nlm.nih.gov/PMC2822971/).
8. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marcianti KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nature genetics*. 2010; 42(1):45–52. doi: [10.1038/ng.500](https://doi.org/10.1038/ng.500) PMID: [20010835](https://pubmed.ncbi.nlm.nih.gov/20010835/); PubMed Central PMCID: [PMC2832852](https://pubmed.ncbi.nlm.nih.gov/PMC2832852/).
9. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide association study identifies five loci associated with lung function. *Nature genetics*. 2010; 42(1):36–44. doi: [10.1038/ng.501](https://doi.org/10.1038/ng.501) PMID: [20010834](https://pubmed.ncbi.nlm.nih.gov/20010834/); PubMed Central PMCID: [PMC2862965](https://pubmed.ncbi.nlm.nih.gov/PMC2862965/).
10. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nature genetics*. 2011; 43(11):1082–90. doi: [10.1038/ng.941](https://doi.org/10.1038/ng.941) PMID: [21946350](https://pubmed.ncbi.nlm.nih.gov/21946350/); PubMed Central PMCID: [PMC3267376](https://pubmed.ncbi.nlm.nih.gov/PMC3267376/).
11. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. *PLoS genetics*. 2009; 5(3): e1000429. Epub 2009/03/21. doi: [10.1371/journal.pgen.1000429](https://doi.org/10.1371/journal.pgen.1000429) PMID: [19300500](https://pubmed.ncbi.nlm.nih.gov/19300500/); PubMed Central PMCID: [PMCPmc2652834](https://pubmed.ncbi.nlm.nih.gov/PMC32652834/).

12. Wilk JB, Shrine NR, Loefer LR, Zhao JH, Manichaikul A, Lopez LM, et al. Genome-wide association studies identify *CHRNA5/3* and *HTR4* in the development of airflow obstruction. *American journal of respiratory and critical care medicine*. 2012; 186(7):622–32. Epub 2012/07/28. doi: [10.1164/rccm.201202-0366OC](https://doi.org/10.1164/rccm.201202-0366OC) PMID: [22837378](https://pubmed.ncbi.nlm.nih.gov/22837378/); PubMed Central PMCID: [PMCPmc3480517](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC3480517/).
13. Yao TC, Du G, Han L, Sun Y, Hu D, Yang JJ, et al. Genome-wide association study of lung function phenotypes in a founder population. *The Journal of allergy and clinical immunology*. 2014; 133(1):248–55.e1–10. Epub 2013/08/13. doi: [10.1016/j.jaci.2013.06.018](https://doi.org/10.1016/j.jaci.2013.06.018) PMID: [23932459](https://pubmed.ncbi.nlm.nih.gov/23932459/).
14. Yamada H, Yatagai Y, Masuko H, Sakamoto T, Iijima H, Naito T, et al. Heritability of pulmonary function estimated from genome-wide SNPs in healthy Japanese adults. *Respiratory investigation*. 2015; 53(2):60–7. doi: [10.1016/j.resinv.2014.10.004](https://doi.org/10.1016/j.resinv.2014.10.004) PMID: [25745850](https://pubmed.ncbi.nlm.nih.gov/25745850/).
15. Yatagai Y, Sakamoto T, Yamada H, Masuko H, Kaneko Y, Iijima H, et al. Genomewide association study identifies *HAS2* as a novel susceptibility gene for adult asthma in a Japanese population. *Clin Exp Allergy*. 2014; 44(11):1327–34. doi: [10.1111/cea.12415](https://doi.org/10.1111/cea.12415) PMID: [25251750](https://pubmed.ncbi.nlm.nih.gov/25251750/).
16. Taniguchi N, Konno S, Hattori T, Isada A, Shimizu K, Shimizu K, et al. The CC16 A38G polymorphism is associated with asymptomatic airway hyper-responsiveness and development of late-onset asthma. *Ann Allergy Asthma Immunol*. 2013; 111(5):376–81.e1. Epub 2013/10/16. doi: [10.1016/j.anaai.2013.08.005](https://doi.org/10.1016/j.anaai.2013.08.005) PMID: [24125144](https://pubmed.ncbi.nlm.nih.gov/24125144/).
17. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. *Thorax*. 2007; 62(11):932–7. Epub 2007/06/19. doi: [10.1136/thx.2006.072777](https://doi.org/10.1136/thx.2006.072777) PMID: [17573447](https://pubmed.ncbi.nlm.nih.gov/17573447/); PubMed Central PMCID: [PMCPMC2117136](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC2117136/).
18. [Guideline of respiratory function tests—spirometry, flow-volume curve, diffusion capacity of the lung]. *Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society*. 2004; Suppl:1–56. PMID: [15565748](https://pubmed.ncbi.nlm.nih.gov/15565748/).
19. Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, et al. An interaction between *Nrf2* polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study. *BMC medical genetics*. 2011; 12:97. Epub 2011/07/22. doi: [10.1186/1471-2350-12-97](https://doi.org/10.1186/1471-2350-12-97) PMID: [21774808](https://pubmed.ncbi.nlm.nih.gov/21774808/); PubMed Central PMCID: [PMCPmc3160350](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC3160350/).
20. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria; 2014. Available: <http://www.R-project.org>. Accessed 6 April 2015.
21. Raychaudhuri S, Plenge RM, Rossin EJ, Ng AC, Purcell SM, Sklar P, et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS genetics*. 2009; 5(6):e1000534. Epub 2009/06/27. doi: [10.1371/journal.pgen.1000534](https://doi.org/10.1371/journal.pgen.1000534) PMID: [19557189](https://pubmed.ncbi.nlm.nih.gov/19557189/); PubMed Central PMCID: [PMCPmc2694358](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC2694358/).
22. Raychaudhuri S. VIZ-GRAIL: visualizing functional connections across disease loci. *Bioinformatics*. 2011; 27(11):1589–90. Epub 2011/04/21. doi: [10.1093/bioinformatics/btr185](https://doi.org/10.1093/bioinformatics/btr185) PMID: [21505031](https://pubmed.ncbi.nlm.nih.gov/21505031/); PubMed Central PMCID: [PMCPMC3102227](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC3102227/).
23. Kreiner-Moller E, Bisgaard H, Bonnelykke K. Prenatal and postnatal genetic influence on lung function development. *The Journal of allergy and clinical immunology*. 2014; 134(5):1036–42.e15. Epub 2014/05/27. doi: [10.1016/j.jaci.2014.04.003](https://doi.org/10.1016/j.jaci.2014.04.003) PMID: [24857373](https://pubmed.ncbi.nlm.nih.gov/24857373/).
24. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. *Lancet*. 2015; 385(9971):899–909. Epub 2014/08/16. doi: [10.1016/s0140-6736\(14\)60446-3](https://doi.org/10.1016/s0140-6736(14)60446-3) PMID: [25123778](https://pubmed.ncbi.nlm.nih.gov/25123778/).
25. Kaneko Y, Yatagai Y, Yamada H, Iijima H, Masuko H, Sakamoto T, et al. The search for common pathways underlying asthma and COPD. *International journal of chronic obstructive pulmonary disease*. 2013; 8:65–78. doi: [10.2147/COPD.S39617](https://doi.org/10.2147/COPD.S39617) PMID: [23378757](https://pubmed.ncbi.nlm.nih.gov/23378757/); PubMed Central PMCID: [PMC3558318](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC3558318/).
26. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. *Thorax*. 2015; 70(7):683–91. Epub 2015/05/08. doi: [10.1136/thoraxjnl-2014-206740](https://doi.org/10.1136/thoraxjnl-2014-206740) PMID: [25948695](https://pubmed.ncbi.nlm.nih.gov/25948695/).
27. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. *The Journal of allergy and clinical immunology*. 2011; 127(2):382–9.e1–13. Epub 2011/01/05. doi: [10.1016/j.jaci.2010.11.015](https://doi.org/10.1016/j.jaci.2010.11.015) PMID: [21195471](https://pubmed.ncbi.nlm.nih.gov/21195471/); PubMed Central PMCID: [PMCPMC3060668](https://pubmed.ncbi.nlm.nih.gov/PMC/PMC3060668/).
28. Lodrup Carlsen KC, Mowinckel P, Hovland V, Haland G, Riiser A, Carlsen KH. Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity. *The Journal of allergy and clinical immunology*. 2014; 134(4):917–23.e7. Epub 2014/07/07. doi: [10.1016/j.jaci.2014.05.020](https://doi.org/10.1016/j.jaci.2014.05.020) PMID: [24997636](https://pubmed.ncbi.nlm.nih.gov/24997636/).
29. Bartis D, Mise N, Mahida RY, Eickelberg O, Thickett DR. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? *Thorax*. 2014; 69(8):760–5. Epub 2013/12/18. doi: [10.1136/thoraxjnl-2013-204608](https://doi.org/10.1136/thoraxjnl-2013-204608) PMID: [24334519](https://pubmed.ncbi.nlm.nih.gov/24334519/).